Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn and above all else, discover the new opportunities and potential partnerships that will deliver the innovations of the future. In short, to make new deals.

The challenging economy and the associated state of the stock markets has made the last 18 months tough for players of every size in the industry. But are we about to turn a corner?

Download now to read Evaluate's latest market report.


The current state of dealmaking
The drivers for the next wave of deals
How the second quarter has found a couple of important indicators looking up